PI3King on MYCN to Improve Neuroblastoma Therapeutics

[摘要]：MYCN is an oncogenic driver of childhood neuroblastoma, a frequently lethal pediatric tumor. In a recent paper in Science Translational Medicine, Chanthery and colleagues demonstrate that PI3K inhibition leads to the dual therapeutic benefits of enhanced MYCN degradation and loss of a paracrine angiogenic signal mediated by MYCN.

[全文传递流程]：

一般上传文献全文的时限在1个工作日内